Quantcast

Latest Clinical trial Stories

2014-06-24 16:24:29

G-202 Data in HCC Patients (Phase I and Phase II) Highly Suggestive of Positive Clinical Activity SAN ANTONIO, June 24, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at...

2014-06-24 10:00:46

BMJ-British Medical Journal May be time to review current restrictive guidance in UK and elsewhere Prisoners are being unfairly excluded from taking part in potentially beneficial clinical research, on the grounds that it would be too difficult and expensive to do so, indicates a study published online in the Journal of Medical Ethics. And current guidance governing research in prisons is too 'protectionist' and restrictive, denying prisoners the chance to access the same research...

2014-06-23 16:25:24

BRIDGEWATER, N.J., June 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin® for use in hemodialysis patients with a central venous catheter....

2014-06-23 08:29:39

- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen(®) and Synacthen(®) Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid...

2014-06-23 08:27:20

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today that they have met all regulatory requirements from Germany's BfArM to initiate a Phase II clinical trial of VPD-737 (serlopitant) in patients with prurigo nodularis. Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus. "Prurigo nodularis...

2014-06-23 04:20:31

LONDON, June 23, 2014 /PRNewswire/ -- Highlights: - Creation of an international CRO with complete service offering from Phase I to Phase IV post-authorisation studies - Appointment of a highly experienced Board, including Professor Trevor Jones CBE, Chairman, Ronald Openshaw, Chief Executive Officer and Professor Sir Christopher Evans, Non-Executive Director - Completed with GBP12.5m of funds raised from Welsh...

2014-06-20 08:23:49

Company Refutes Latest Feuerstein False Headline and Attacks BETHESDA, Md., June 20, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein's latest false headline and attack on the Company, and reaffirmed the Company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors....

2014-06-19 23:11:43

In this webinar, speakers Wendy Stewart, VP and Integrated Site Start up at Quintiles along with Sam Searcy, Associate Contracts Services Director and Global Regulatory Start Up at Quintiles, will demonstrate how some strategies, processes, and technology help maximize productivity and reduce cycle times. The live broadcast will be taking place on Thursday, July 10, 2014 at 11 a.m. EDT / 4p.m. BST (UK GMT +1). Toronto, Canada (PRWEB) June 19, 2014 In the early stages of a clinical study,...

2014-06-19 16:26:20

SAN DIEGO, June 19, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. "We are delighted to welcome Howard to the Board," stated Jack Lief, Chair of Mast's Board of Directors. "His medical training and extensive clinical development and...

2014-06-19 08:28:24

REDWOOD CITY, Calif., June 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 25th. Presentation details are as follows: JMP Securities Healthcare ConferenceDate: Wednesday, June 25thLocation: The Westin New York Grand Central,...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related